{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:49:22Z","timestamp":1788824962405,"version":"build-2803163510"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1097\/wnf.0000000000000086","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T21:35:00Z","timestamp":1436650500000},"page":"121-126","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Tardive Dystonia Induced by Antipsychotics, Old and New"],"prefix":"10.1097","volume":"38","author":[{"given":"Philippos","family":"Gourzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Skokou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Soubasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggeliki","family":"Katrivanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Polychronopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"e25588","DOI":"10.1371\/journal.pone.0025588","article-title":"Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder.","volume":"6","author":"Bakker","year":"2011","journal-title":"PLoS One"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0006-3223(98)00242-X","article-title":"The current status of tardive dystonia.","volume":"45","author":"Adityanjee, Aderibigbe","year":"1999","journal-title":"Biol Psychiatry"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/oxfordjournals.schbul.a033415","article-title":"Tardive dystonia.","volume":"25","author":"van Harten","year":"1999","journal-title":"Schizophr Bull"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.319.7210.623","article-title":"Fortnightly reviewacute dystonia induced by drug treatment.","volume":"319","author":"van Harten","year":"1999","journal-title":"BMJ"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ncl.2010.10.002","article-title":"Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.","volume":"29","author":"Caroff","year":"2011","journal-title":"Neurol Clin"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/brain\/121.11.2053","article-title":"The natural history of tardive dystonia. A long-term follow-up study of 107 cases.","volume":"121","author":"Kiriakakis","year":"1998","journal-title":"Brain"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.pra.0000388631.67275.16","article-title":"A biopsychosocial approach to improving quality of life in tardive dystonia.","volume":"16","author":"Buscombe","year":"2010","journal-title":"J Psychiatr Pract"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1176\/jnp.16.1.29","article-title":"Differential DSM-111 psychiatric disorder prevalence profiles in dystonia and Parkinsons disease.","volume":"16","author":"Lauterbach","year":"2004","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCP.0b013e3181929f94","article-title":"Mortality rates among patients with schizophrenia and tardive dyskinesia.","volume":"29","author":"Chong","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4088\/JCP.v66n0907","article-title":"Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.","volume":"66","author":"Tenback","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics.","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophreniaCost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1176\/ajp.156.7.1097","article-title":"Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness.","volume":"156","author":"Arango","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.eurpsy.2009.12.006","article-title":"Subjective awareness of tardive dyskinesia and insight in schizophrenia.","volume":"26","author":"Emsley","year":"2011","journal-title":"Eur Psychiatry"},{"key":"R17-1-20210203","first-page":"39","article-title":"The treatment of tardive dyskinesia and tardive dystonia.","volume":"61","author":"Simpson","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0278-5846(95)00309-6","article-title":"Use of clozapine in tardive dystonia.","volume":"20","author":"Van Harten","year":"1996","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","article-title":"The emerging role of clozapine in the treatment of improvement disorders.","volume":"12","author":"Factor","year":"1997","journal-title":"Mov Disord"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/0269881109103827","article-title":"Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics Case report and brief review of the literature.","volume":"24","author":"Peritogiannis","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/jcp.0b013e318160864f","article-title":"Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.","volume":"28","author":"Cortese","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","article-title":"A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.","volume":"65","author":"Emsley","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R23-1-20210203","first-page":"347","article-title":"Utility of quetiapine in tardive dyskinesia. Utilidad de la quetiapina en la discinesia tardia.","volume":"31","author":"Navarro Pacheco","year":"2003","journal-title":"Actas Esp Psiquiatr"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.918","article-title":"Neurological complications of psychiatric drugs: clinical features and management.","volume":"23","author":"Haddad","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0924-9338(02)00647-8","article-title":"Tardive dyskinesias and antipsychotics: a review.","volume":"17","author":"Llorca","year":"2002","journal-title":"Eur Psychiatry"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244923","article-title":"Seroquel: biochemical profile of a potential atypical antipsychotic.","volume":"112","author":"Saller","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","article-title":"Quetiapine for the treatment of drug-induced psychosis in Parkinsons disease.","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov Disord"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.nrl.0000038585.58012.97","article-title":"Classification and treatment of tardive syndromes.","volume":"9","author":"Fernandez","year":"2003","journal-title":"Neurologist"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/WNL.35.1.73","article-title":"Validity and reliability of a rating scale for the primary torsion dystonias.","volume":"35","author":"Burke","year":"1985","journal-title":"Neurology"},{"key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0920-9964(95)00096-8","article-title":"The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curacao extrapyramidal syndromes study: I.","volume":"19","author":"Van Harten","year":"1996","journal-title":"Schizophr Res"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0269881105056668","article-title":"Switching antipsychotics: an updated review with a focus on quetiapine.","volume":"20","author":"Weiden","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R34-1-20210203","first-page":"306","article-title":"Quetiapine treatment of risperidone-related tardive dyskinesia. A case report.","volume":"31","author":"Lapaz","year":"2003","journal-title":"Actas Esp Psiquiatr"},{"key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.wnf.0000174933.89758.c9","article-title":"Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychoticsa report of 2 cases.","volume":"28","author":"Gourzis","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R36-1-20210203","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jocn.2006.04.006","article-title":"Quetiapine successfully treating oculogyric crisis induced by antipsychotic drugs.","volume":"14","author":"Gourzis","year":"2007","journal-title":"J Clin Neurosci"},{"key":"R37-1-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/0269881108089591","article-title":"A case of aripiprazole and tardive dyskinesia.","volume":"23","author":"Abbasian","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R38-1-20210203","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00004850-200209000-00006","article-title":"Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia.","volume":"17","author":"Alptekin","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/0269881104040251","article-title":"Atypical antipsychotic drugs and tardive dyskinesia: relevance of D 2 receptor affinity.","volume":"18","author":"Bressan","year":"2004","journal-title":"J Psychopharmacol"},{"key":"R40-1-20210203","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00023210-199911060-00005","article-title":"The role of atypical antipsychotics in the treatment of movement disorders.","volume":"11","author":"Fernandez","year":"1999","journal-title":"CNS Drugs"},{"key":"R41-1-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2832-2-9","article-title":"Treatment of severe neuroleptic-induced tardive torticollis.","volume":"2","author":"Havaki-Kontaxaki","year":"2003","journal-title":"Ann Gen Hosp Psychiatry"},{"key":"R42-1-20210203","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/mds.20904","article-title":"Botulinum toxin as a treatment for tardive dyskinesia.","volume":"21","author":"van Harten","year":"2006","journal-title":"Mov Disord"},{"key":"R43-1-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870010305","article-title":"Natural history and treatment of tardive dystonia.","volume":"1","author":"Kang","year":"1986","journal-title":"Mov Disord"},{"key":"R44-1-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00002826-200009000-00002","article-title":"Dystonia update.","volume":"23","author":"Bressman","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"R45-1-20210203","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00701-009-0281-x","article-title":"Deep brain stimulation for secondary dystonia: results in 8 patients.","volume":"151","author":"Katsakiori","year":"2009","journal-title":"Acta Neurochir (Wien)"},{"key":"R46-1-20210203","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01245320","article-title":"An experimental model of tardive dyskinesia.","volume":"33","author":"Klawans Jr","year":"1972","journal-title":"J Neural Transm"},{"key":"R47-1-20210203","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/newbio245262a0","article-title":"Pharmacologically induced behavioural supersensitivity to apomorphine.","volume":"245","author":"Tarsy","year":"1973","journal-title":"Nat New Biol"},{"key":"R48-1-20210203","first-page":"25","article-title":"Pathophysiology of antipsychotic drug-induced movement disorders.","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R49-1-20210203","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4088\/JCP.v62n1001","article-title":"Hit-and-Run actions at dopamine receptors, part 2: Illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics.","volume":"62","author":"Stahl","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R50-1-20210203","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S0924-977X(01)00111-0","article-title":"Quetiapine: efficacy and tolerability in schizophrenia.","volume":"11","author":"Kasper","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"R51-1-20210203","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.156.6.876","article-title":"Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.","volume":"156","author":"Seeman","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R52-1-20210203","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol Psychiatry"},{"key":"R53-1-20210203","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics A new hypothesis.","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R54-1-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/10401230109147385","article-title":"Iatrogenic disorders associated with conventional vs. atypical antipsychotics.","volume":"13","author":"Nasrallah","year":"2001","journal-title":"Ann Clin Psychiatry"},{"key":"R55-1-20210203","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10673229.2011.614100","article-title":"Rational antipsychotic choice: weighing the risk of tardive dyskinesia and metabolic syndrome.","volume":"19","author":"Stoklosa","year":"2011","journal-title":"Harv Rev Psychiatry"},{"key":"R56-1-20210203","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.1993.01820210057007","article-title":"Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study.","volume":"50","author":"Morgenstern","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R57-1-20210203","doi-asserted-by":"crossref","first-page":"212259","DOI":"10.7573\/dic.212259","article-title":"Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.","volume":"3","author":"Kim","year":"2014","journal-title":"Drugs Context"},{"key":"R58-1-20210203","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/0269881107073257","article-title":"The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.","volume":"21","author":"Twaites","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R60-1-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852900026651","article-title":"Implications of the CATIE trial on treatment: extrapyramidal symptoms.","volume":"11","author":"Casey","year":"2006","journal-title":"CNS Spectr"},{"key":"R61-1-20210203","first-page":"589","article-title":"Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics Mov D","volume":"21","author":"Tarsy","year":"2006","journal-title":"isord"},{"key":"R62-1-20210203","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.schres.2006.07.025","article-title":"Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE.","volume":"88","author":"De Hert","year":"2006","journal-title":"Schizophr Res"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T05:22:24Z","timestamp":1691817744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201507000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000086","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}